The evaluation of the immunohistochemical expression of FADD must jointly consider nuclear and cytoplasmic overexpression since these intracellular locations were exclusively those that significantly influenced the prognosis (HR = 1.54, 95% CI = 1.25–1.91, p < 0.001), while studies only considering FADD cytoplasmic labelling did not show a relationship with tumour prognosis. This evidence concerns the gene FADD and neoplasm.